肠道通透性受损与炎症性肠病黏膜愈合患者持续肠道症状相关
这项在澳大利亚悉尼开展的前瞻性研究纳入110例受试者(31例溃疡性结肠炎、57例克罗恩病、22例健康对照),用内镜共聚焦激光显微内镜测量肠道通透性。黏膜愈合的炎症性肠病患者中16.3%仍有肠道症状,有症状者中位共聚焦渗漏评分19.0,高于无症状者7.3和对照5.9;共聚焦渗漏评分13.1及以上识别持续症状的灵敏度95.2%、特异度97.6%。
要点
- 黏膜愈合的炎症性肠病患者中16.3%仍有腹泻或腹痛症状。
- 有症状者中位共聚焦渗漏评分19.0,高于无症状者7.3和对照5.9。
- 共聚焦渗漏评分13.1及以上识别症状的灵敏度95.2%、特异度97.6%。
核心结论
- 在黏膜愈合的炎症性肠病患者中,肠道通透性受损与持续肠道症状相关,通透性增加与腹泻严重程度增加相关。
- 解决黏膜通透性异常可能改善炎症性肠病患者的结局。
研究设计与样本
- 前瞻性研究,2009年5月至2015年9月在澳大利亚悉尼连续纳入110例受试者,包括31例溃疡性结肠炎、57例克罗恩病和22例健康对照。
- 用内镜共聚焦激光显微内镜测量肠道通透性,以共聚焦渗漏评分(范围0=无通透性受损至100=屏障功能完全丧失)量化。
- 有症状克罗恩病定义为克罗恩病活动指数评分150及以上,有症状溃疡性结肠炎定义为部分Mayo评分2及以上;黏膜愈合定义为克罗恩病内镜严重程度指数为0或溃疡性结肠炎Mayo内镜子评分为0-1。
- 主要终点为黏膜愈合的有症状炎症性肠病患者与黏膜愈合的无症状炎症性肠病患者的肠道通透性比较。
主要发现
- 黏膜愈合的炎症性肠病患者中16.3%存在持续肠道症状(克罗恩病15.4%,溃疡性结肠炎17.4%)。
- 有症状炎症性肠病患者中位共聚焦渗漏评分19.0,高于无症状炎症性肠病患者7.3(P < .001)和健康对照5.9(P < .001)。
- 缓解期炎症性肠病患者与健康对照的中位共聚焦渗漏评分无显著差异(P = .261)。
- 有症状克罗恩病患者中位共聚焦渗漏评分17.7,高于无症状克罗恩病患者8.1(P = .009);有症状溃疡性结肠炎患者22.2,高于无症状溃疡性结肠炎患者6.9(P = .021)。
- 共聚焦渗漏评分13.1及以上识别黏膜愈合炎症性肠病患者持续肠道症状的灵敏度95.2%、特异度97.6%,受试者操作特征曲线下面积0.88;按此界值,36.2%的黏膜愈合炎症性肠病患者肠道通透性增加。
关键数值与推荐
- 有症状克罗恩病:克罗恩病活动指数评分150及以上;有症状溃疡性结肠炎:部分Mayo评分2及以上。
- 黏膜愈合:克罗恩病内镜严重程度指数为0;溃疡性结肠炎Mayo内镜子评分为0-1。
- 共聚焦渗漏评分范围0(无通透性受损)至100(屏障功能完全丧失)。
- 共聚焦渗漏评分13.1及以上识别持续肠道症状的灵敏度95.2%、特异度97.6%,曲线下面积0.88。
- 共聚焦渗漏评分每增加1.9与每日腹泻次数增加1次相关(P = .008)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Many patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal healing. We investigated whether impaired intestinal permeability contributes to these symptoms. METHODS: We performed a prospective study of intestinal permeability, measured by endoscopic confocal laser endomicroscopy in 110 consecutive subjects (31 with ulcerative colitis [UC], 57 with Crohn's disease [CD], and 22 healthy individuals [controls]) in Sydney, Australia from May 2009 and September 2015. Symptomatic CD was defined by a CD Activity Index score of 150 or more and symptomatic UC by a partial Mayo score of 2 or more. Mucosal healing was defined as CD Endoscopic Index of Severity of 0 in CD or Mayo endoscopic sub-score of 0-1 for patients with UC. Intestinal permeability was quantified by the Confocal Leak Score (CLS; range: 0=no impaired permeability to 100=complete loss of barrier function). The primary endpoint was intestinal permeability in patients with symptomatic IBD in mucosal healing vs patients with asymptomatic IBD in mucosal healing. We determined the sensitivity and specificity of CLS in determining symptoms based on receiver operating characteristic analysis. RESULTS: Ongoing bowel symptoms were present in 16.3% of patients with IBD and mucosal healing (15.4% of patients with CD, 17.4% with UC). Patients with symptomatic IBD had a significantly higher median CLS (19.0) than patients with asymptomatic IBD (7.3; P < .001) or controls (5.9, P < .001). There were no significant differences between patients with IBD in remission vs controls (P = .261). Median CLS was significantly higher in patients with symptomatic than asymptomatic CD (17.7 vs 8.1; P = .009) and patients with symptomatic than asymptomatic UC (22.2 vs 6.9; P = .021). A CLS of 13.1 or more identified ongoing bowel symptoms in patients with IBD and mucosal healing with 95.2% sensitivity and 97.6% specificity; the receiver operating characteristic area under curve value was 0.88. Based on this cutoff, 36.2% of patients with IBD in mucosal healing have increased intestinal permeability. On regression analysis, every increase in CLS of 1.9 correlated with an additional diarrheal motion per day (P = .008). CONCLUSIONS: In a prospective study of intestinal permeability in patients with IBD and mucosal healing, we associated impaired intestinal permeability with ongoing bowel symptoms; increases in permeability correlated with increased severity of diarrhea. Resolution of mucosal permeability beyond mucosal healing might improve outcomes of patients with IDB (ANZCTR.org.au: ACTRN12613001248752).
引用
- Chang J, Leong RW, Wasinger VC, et al. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing. Gastroenterology. 2017. PMID: 28601482. doi:10.1053/j.gastro.2017.05.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。